Anti-BCMA Antibody Drug Conjugates for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody drug conjugates (ADCs) face challenges in selectively targeting cancer cells while minimizing toxicity to normal cells, particularly in delivering effective drug moieties to tumor tissues, as they often result in non-specific toxicity due to systemic administration.
Innovation Solution
Development of ADCs comprising an anti-BCMA antibody conjugated through linker moieties, which selectively binds to BCMA-expressing cancer cells, allowing for targeted delivery of a drug moiety and reducing non-specific toxicity by utilizing monoclonal antibodies such as anti-BCMA, anti-ROR1, anti-CD25, or anti-Claudine 18 antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ADCs are administered systemically to deliver drug moieties to tumor tissues, then anti-tumor efficacy is improved, but non-specific toxicity to normal cells increases
Solution Approach 1:
The patent applies local quality by designing ADCs with tumor-specific targeting moieties (anti-BCMA antibodies, anti-ROR1 antibodies, etc.) that confer selective binding capability to tumor cells. This allows the drug moiety to be delivered preferentially to tumor tissues rather than distributed systemically, thereby maintaining anti-tumor efficacy while reducing non-specific toxicity to normal cells through localized action at the tumor site
Solution Approach 2:
The patent employs targeting moieties (antibodies, antibody fragments, or binding proteins) as intermediaries that mediate between the drug moiety and tumor cells. These intermediaries enable selective recognition and binding to tumor-specific antigens (such as BCMA or ROR1), facilitating targeted delivery of the cytotoxic drug to tumor tissues while minimizing exposure of normal cells to the drug, thus resolving the contradiction between efficacy and toxicity
2Reliability
If conventional chemotherapy is administered to treat cancer, then tumor cells are killed, but normal cells are also damaged due to lack of selectivity
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic agent into distinct functional components: a targeting moiety (antibody or binding protein) and a drug moiety (cytotoxic agent). The targeting moiety is responsible for selective recognition and binding to tumor cells, while the drug moiety provides the cytotoxic effect. This segmentation allows the drug to be delivered selectively to cancer cells through the targeting moiety, thereby maintaining cancer cell killing efficacy while minimizing damage to normal cells that lack the target antigen
Solution Approach 2:
The patent uses targeting moieties as intermediaries that bridge the gap between conventional chemotherapy and selective cancer cell killing. These intermediaries (antibodies or binding proteins) confer tumor-specific targeting capability to the cytotoxic drug, enabling selective accumulation of the drug in tumor tissues. This intermediary approach transforms non-selective chemotherapy into targeted therapy, maintaining efficacy against cancer cells while reducing toxicity to normal cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADCs demonstrate potent anti-tumor activity by selectively delivering the drug moiety to BCMA-expressing cancer cells, enhancing therapeutic index and minimizing off-target toxicity, as shown in in vitro and in vivo efficacy studies, effectively treating BCMA-expressing cancers like multiple myeloma.
Implementation Method 1
the anti-BCMA antibody binds to BCMA-expressing cancer cells and allows for selective uptake of the ADC into the cancer cells
Data Source
AI summary
Provided, inter alia, are antibody drug conjugates (ADCs) which specifically bind B Cell Maturation Antigen (BCMA). Further disclosed are pharmaceutical compositions, and methods for treating cancer.